Research and registries

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) Trial


The PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) Trial is the first large-scale, multi-specialty, prospective clinical study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States. With the guidance of the Food and Drug Administration (FDA), the study will help determine how well filters prevent pulmonary embolisms and when retrievable filters should be removed, thus advancing patient safety. 

The trial is sponsored by the IVC Filter Study Group Foundation, a joint collaboration between the Society of Interventional Radiology and the Society for Vascular Surgery. 

Currently, the study is recruiting patients. For additional information about participating sites, please visit

<p>To learn more about the trial, please visit the&nbsp;<a title="PRESERVE Trial" href="" target="_blank">PRESERVE</a>&nbsp;website.</p>

To learn more about the trial, please visit the PRESERVE website.

PRESERVE achieves midway milestone

As of June 2017, with its enrollment of 903 subjects, PRESERVE has reached its midway milestone with the overall goal of enrolling 1,800 subjects. Each site is expected to enroll one subject per month. Currently, Northwestern Memorial Hospital is leading enrollment among the 47 active sites. If you have any questions about PRESERVE, please contact  Eleanore Moye.


PRESERVE Enrollment

What is the significance of the PRESERVE Trial?

Listen to Matthew Johnson, MD, FSIR, the co-chair of the PRESERVE Steering Committee, discuss the background and current status of this important initiative.